• Journal of the Korean Society of Laryngology, Phoniatrics and Logopedics
• /
• v.26 no.1
• /
• pp.46-50
• /
• 2015

Background and Objectives:Laryngeal hyperkinetic movements of stuttering patients is similar to that of adductor spasmodic dysphonia. There has been studies on implementing botulinium toxin injections to treat stuttering. However, the opinions on the bouolinium toxin injection's effects on stuttering patients vary. In this study authors aim to figure out when the botulinium toxin injection improves stuttering patients. Materials and Methods:Stuttering patients who could receive botulinium toxin injection participated in this study. Age differences, gender differences, electroglottogrphic test, aerodynamic test in botulinium toxin injection treatment of stuttering were analyzed. Results:The botulinium toxin injection had statistically significant impact on patients who showed low mean air flow rate during aerodynamic study. Conclusion:The botulinium toxin injection could reduce stuttering of patients with low mean air flow rate in aerodynamic study.

• BMB Reports
• /
• v.31 no.1
• /
• pp.101-105
• /
• 1998

Immunoassay of botulinum toxin (BTX) B type was investigated using two typed of biosensors: light addressable potentiometric sensor (LAPS) and surface plasmon resonance (SPR) sensor. Urease-tagged and immuno-filtration capture method have been used for LAPS. Tag-free and direct binding real-time detection method have been used for SPR sensor. The detection limit of sandwich assay format with LAPS was 10 ng/ml, which was the lowest among methods tested. SPR has the advantage of being more convenient because tag-free direct binding assay can be used and reaction time was reduced, regardless of low sensitivity. This result shows that sandwich assay format with LAPS can be used as an alternative method of BTX mouse bioassay which is known as the most sensitive method for the detection of BTX.

• International Journal of Oral Biology
• /
• v.40 no.2
• /
• pp.71-77
• /
• 2015

The activation of glial cells in the spinal cord has been contribute to the initiation and maintenance of pain facilitation induced by peripheral inflammation and nerve injury. The present study investigated effects of botulinum toxin type A (BoNT-A), injected subcutaneously or intracisternally, on the expression of microglia and astrocytes in rats. Complete Freund's Adjuvant (CFA)-induced inflammation was employed as an orofacial chronic inflammatory pain model. A subcutaneous injection of $40{\mu}L$ CFA into the vibrissa pad was performed under 3% isoflurane anesthesia in SD rats. Immunohistochemical analysis for changes in Iba1 (a microglia marker) and GFAP (an astrocyte marker), were performed 5 days after CFA injection. Subcutaneous injection of CFA produced increases in Iba1 and GFAP expression, in the ipsilateral superficial lamia I and II in the medullary dorsal horn of rats. Subcutaneous treatment with BoNT-A attenuated the up-regulation of Iba1 and GFAP expressions induced by CFA injection. Moreover, intracisternal injection of BoNT-A also attenuated the up-regulated Iba1 and GFAP expressions. These results suggest that the anti-nociceptive action of BoNT-A is mediated by modulation activation of glial cells, including microglia and astrocyte.